Clinical Trial Update: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluating oral letermovir for CMV prophylaxis in thoracic transplant recipients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: University of Pennsylvania | Conditions: Cytomegalovirus Infections, Transplant-Related Disorder | Phase 2 | Status: RECRUITING